Maxcyte (MXCT) Accumulated Depreciation & Amortization (2020 - 2026)

Maxcyte (MXCT) has 7 years of Accumulated Depreciation & Amortization data on file, last reported at -$11.1 million in Q1 2026.

• Quarterly Accumulated Depreciation & Amortization fell 77.59% year-over-year to -$11.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$11.1 million (down 77.59% YoY) and the FY2025 annual result came in at -$5.0 million, up 71.82% from the prior year.
• Accumulated Depreciation & Amortization fell to -$11.1 million in Q1 2026 per MXCT's latest filing, from -$5.0 million in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at -$3.8 million in Q3 2025 and bottomed at -$21.1 million in Q1 2023.
• The 5-year median for Accumulated Depreciation & Amortization is -$11.2 million (2023), against an average of -$11.8 million.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization slumped 723.26%; it then surged 71.82% in 2025.
• Tracing MXCT's Accumulated Depreciation & Amortization over 5 years: stood at -$14.2 million in 2022, then advanced by 21.0% to -$11.2 million in 2023, then plunged by 57.7% to -$17.7 million in 2024, then surged by 71.82% to -$5.0 million in 2025, then plunged by 123.33% to -$11.1 million in 2026.
• Per Business Quant, the three latest MXCT Accumulated Depreciation & Amortization figures stand at -$11.1 million (Q1 2026), -$5.0 million (Q4 2025), and -$3.8 million (Q3 2025).

Peer Comparison